AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
BPI-572270 enters clinical trials.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
Persevera is a bust, but Roche hasn’t given up on the front line.
Ono's antisense therapy is to begin its first pivotal trial.
The company pays $2.5bn for Day One and its approved drug Ojemda.
